Cargando…

Correction to: Real-world treatment of over 1600 Japanese patients with EGFR mutation-positive non-small cell lung cancer with daily afatinib

Detalles Bibliográficos
Autores principales:	Tamura, Kazuo, Nukiwa, Toshihiro, Gemma, Akihiko, Yamamoto, Nobuyuki, Mizushima, Masaya, Ochai, Kaori, Ikeda, Rie, Azuma, Hisaya, Nakanishi, Yoichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Singapore 2019
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6687701/ https://www.ncbi.nlm.nih.gov/pubmed/31240497 http://dx.doi.org/10.1007/s10147-019-01488-w

Ejemplares similares

Real-world treatment of over 1600 Japanese patients with EGFR mutation-positive non-small cell lung cancer with daily afatinib
por: Tamura, Kazuo, et al.
Publicado: (2019)

A phase II study of first-line afatinib for patients aged ≥75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027
por: Minegishi, Yuji, et al.
Publicado: (2021)

Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib
por: Yamamoto, Nobuyuki, et al.
Publicado: (2019)

Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor–naïve patients with non–small cell lung cancer harboring EGFR mutations
por: Tanaka, Kentaro, et al.
Publicado: (2017)

Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer
por: Takahashi, Akiko, et al.
Publicado: (2018)

FGFR1 activation is an escape mechanism in human lung cancer cells resistant to afatinib, a pan-EGFR family kinase inhibitor
por: Azuma, Koichi, et al.
Publicado: (2014)

Double-blind controlled trial of lecithinized superoxide dismutase in patients with idiopathic interstitial pneumonia – short term evaluation of safety and tolerability
por: Kamio, Koichiro, et al.
Publicado: (2014)

Is there a role for sequential afatinib and osimertinib in patients with EGFR mutation?
por: Iwamoto, Natsuhiko, et al.
Publicado: (2022)

Response to Afatinib in a Common EGFR-Mutated Lung Adenocarcinoma with a Very Rare Combination of Compound Mutations
por: Satoh, Hiroaki, et al.
Publicado: (2022)

Calderón, 1600-2000 /
Publicado: (2002)

Fable, c. 1600
por: Potter, Polyxeni
Publicado: (2002)

Successful Treatment with Afatinib after Osimertinib-induced Interstitial Lung Disease in a Patient with EGFR-mutant Non-small-cell Lung Cancer
por: Nishima, Shunichi, et al.
Publicado: (2020)

Anti-inflammatory effect of afatinib (an EGFR-TKI) on OGD-induced neuroinflammation
por: Chen, Yen-Ju, et al.
Publicado: (2019)

Afatinib for the Treatment of NSCLC with Uncommon EGFR Mutations: A Narrative Review
por: Jiang, Yingying, et al.
Publicado: (2023)

Catálogo novogalaico, 1600-1650 /
por: Hernández Bermejo, Evelia
Publicado: (1999)

The language of the heart, 1600–1750
por: Rousseau, G S
Publicado: (1998)

Obstetrics in Mexico Prior to 1600
por: Van Patten, Nathan
Publicado: (1932)

EGFR Mutation Analysis of Circulating Tumor DNA Using an Improved PNA-LNA PCR Clamp Method
por: Watanabe, Kana, et al.
Publicado: (2016)

Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings
por: Harvey, R Donald, et al.
Publicado: (2020)

Afatinib as a Potential Therapeutic Option for Patients With NSCLC With EGFR G724S
por: Wei, Yang, et al.
Publicado: (2021)

Combination of afatinib with cetuximab in patients with EGFR-mutant non-small-cell lung cancer resistant to EGFR inhibitors
por: Ribeiro Gomes, Jéssica, et al.
Publicado: (2015)

Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy
por: Tokudome, Nahomi, et al.
Publicado: (2020)

The activation of SRC family kinases and focal adhesion kinase with the loss of the amplified, mutated EGFR gene contributes to the resistance to afatinib, erlotinib and osimertinib in human lung cancer cells
por: Murakami, Yuichi, et al.
Publicado: (2017)

La comedia española (1600-1680) /
por: Aubrun, Charles Vincent, 1906-
Publicado: (1968)

Arquitectura en Italia,1400-1600
por: Heydenreich, Ludwig H.
Publicado: (2007)

Artistic theory in Italy, 1450-1600 /
por: Blunt, Anthony, 1907-1983
Publicado: (1940)

La guerra chichimeca, 1550-1600
por: Powell, Phillip Wayne
Publicado: (1977)

La guerra chichimeca (1550-1600)
por: Powell, Phillip Wayne
Publicado: (1984)

La guerra Chichimeca (1550 - 1600)
por: Powell, Philip Wayne
Publicado: (1977)

Pintura en Italia, 1500-1600
por: Freedberg, Sydney Joseph, 1914-
Publicado: (1998)

Arquitectura en Italia,1400-1600
por: Heydenreich, Ludwig H.
Publicado: (1991)

London's immigrant apothecaries, 1600-1800.
por: Matthews, L G
Publicado: (1974)

The decay scheme of the $\rho'$ (1600)meson
por: Bernaber, I R, et al.
Publicado: (1974)

Discovering the principles of mechanics: 1600 - 1800
por: Speiser, David, et al.
Publicado: (2008)

Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases
por: Tan, Wan-Ling, et al.
Publicado: (2018)

Author Correction: Anti-inflammatory effect of afatinib (an EGFR-TKI) on OGD-induced neuroinflammation
por: Chen, Yen-Ju, et al.
Publicado: (2021)

Comprehensive assessment of pretreatment sarcopenia impacts on patients with EGFR ‐mutated NSCLC treated with afatinib
por: Wu, Chen‐Te, et al.
Publicado: (2023)

Meter in music, 1600-1800 : performance, perception, and notation /
por: Houle, George
Publicado: (1987)

The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations
por: Yang, Chih-Jen, et al.
Publicado: (2017)

Phase I study of afatinib plus bevacizumab in patients with advanced non-squamous non-small cell lung cancer harboring EGFR mutations
por: Ko, Ryo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4m47vsmlj422stfo8srki7t5h3